# Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery

> **NCT00290355** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 182 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **BIOLOGICAL:** GSK 249553 vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00290355
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05-28
- **Primary completion:** 2011-07-19
- **Final completion:** 2011-07-19
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290355, "Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00290355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*